• PDF / 278,462 Bytes
• 23 Pages / 595.28 x 790.87 pts Page_size
• 33 Downloads / 227 Views

DOWNLOAD

REPORT

---

L.K. Golightly et al. (eds.), Renal Pharmacotherapy, DOI 10.1007/978-1-4614-5800-5_13, © Springer Science+Business Media New York 2013

473

Dosage Adjustment of Medications Eliminated by the Kidneys

Nabumetone - Selected References Aronoff GA. Therapeutic implications associated with renal studies of nabumetone. J Rheumatol. 1992;19(Suppl 36):25–31. Aronoff GA, Bennett WM, Berns JS, et al. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007. Blackwell E, Loughlin K, Dumler F, Smythe M. Nabumetone-associated interstitial nephritis. Pharmacotherapy. 1995;15:669–72. Bolaert JR, Jonnaert HA, Daneels RF, et al. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment. Am J Med. 1987;82(Suppl 4B):107–9. Brier ME, Sloan RS, Aronoff GA. Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. Clin Pharmacol Ther. 1995;57:622–7. Cangiano JL, Figueroa J, Palmer R. Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis. Clin Ther. 1999;21:503–12. Cipiolini F, Ganci A, Panara MR, et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 1995;58:335–41. Cook ME, Wallin JD, Thakur VD, et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol. 1997;24:1137–44. Davies NM. Clinical pharmacokinetics of nabumetone: the dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet. 1997;33:403–16. De Caterina R, Giannessi D, Lazzerini G, et al. Effect of nabumetone on metabolism of renal arachidonate in humans. J Rheumatol. 1992;19(Suppl 36):80. Fleischmann RM. Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. J Rheumatol. 1992;19(Suppl 36):32–40. Freed MI, Audet PR, Zarifa N, et al. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol. 1994;34:1098–108. Freston JW. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med. 1999;107(Suppl 6A):78–89S. Friedel HA, Langtry HD, Buckley MM. Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs. 1993;45:131–56. Giannessi D, Lazzerini G, Filiponi P, et al. Effects of nabumetone, a new non-steroidal anti-inflammatory drug, on urinary prostaglandin excretion in man. Pharmacol Res. 1993;28:229–41. Hedner T, Samulesson O, Währborg P, Wadenvik H, Ung K-A, Ekbom A. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004;64:2315–43. Hynek ML. An overview of the clinical pharmacokinetics of nabumetone. J Rheumatol. 1992;19(Suppl 36):20–4. Kendall MJ, Chellingsworth MC, Jubb R, Thawley AR, Undre NA, Kill DC. A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients. Eur J Clin Pharmacol. 1989;36:299–305. Ma